Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

The Lancet

Volumn 375, Issue 9721, 2010, Pages 1165-1172

  Todo, Yukiharu ^a   Kato, Hidenori ^a   Kaneuchi, Masanori ^b   Watari, Hidemichi ^b   Takeda, Mahito ^b   Sakuragi, Noriaki ^b  

^a HOKKAIDO CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

EID: 77950188128     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62002-X     Document Type: Article

References (24)

1. Roland P.Y., Kelly F.J., Kulwicki C.Y., Blitzer P., Curcio M., and Orr Jr. J.W. The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. Gynecol Oncol 93 (2004) 125-130
2. Watanabe Y., Aoki D., Kitagawa R., et al. Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey. Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group. Gynecol Oncol 105 (2007) 325-328
3. Chan J.K., and Kapp D.S. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 8 (2007) 831-841
4. The writing committee of behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009) 125-136
5. Benedetti-Panici P., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100 (2008) 1707-1716
6. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., and Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. STROBE Initiative. J Clin Epidemiol 61 (2008) 344-349
7. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 60 (1987) 2035-2041
8. Grigsby P.W., Perez C.A., Kuten A., et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 22 (1992) 905-911
9. Nishiya M., Sakuragi N., Hareyama H., et al. Cox multivariate regression model for estimating prognosis of patients with endometrioid adenocarcinoma of the uterine corpus who underwent thorough surgical staging. Int J Cancer 79 (1998) 521-525
10. Sakuragi N., Hareyama H., Todo Y., et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand 79 (2000) 311-316
11. Yaegashi N., Ito K., and Niikura H. Lymphadenectomy for endometrial cancer: is paraaortic lymphadenectomy necessary?. Int J Clin Oncol 12 (2007) 176-180
12. Frederick P.J., and Straughn Jr. M. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control 16 (2009) 23-29
13. Cragun J.M., Havrilesky L.J., Calingaert B., et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23 (2005) 3668-3675
14. Mariani A., Webb M.J., Galli L., and Podratz K.C. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76 (2000) 348-356
15. Fujimoto T., Nanjyo H., Nakamura A., et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol 107 (2007) 253-259
16. Chan J.K., Cheung M.K., Huh W.K., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107 (2006) 1823-1830
17. Lutman C.V., Havrilesky L.J., Cragun J.M., et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 102 (2006) 92-97
18. Mariani A., Dowdy S.C., Cliby W.A., et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109 (2008) 11-18
19. Yokoyama Y., Maruyama H., Sato S., and Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 64 (1997) 411-417
20. Niikura H., Okamura C., Utsunomiya H., et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 92 (2004) 669-674
21. Susumu N., Sagae S., Udagawa Y., et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Japanese Gynecologic Oncology Group. Gynecol Oncol 108 (2008) 226-233
22. Maggi R., Lissoni A., Spina F., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95 (2006) 266-271
23. Randall M.E., Filiaci V.L., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology Group Study. J Clin Oncol 24 (2006) 36-44
24. In: Wittekind C., Greene F.L., Hutter R.V.P., Klimpfinger M., and Sobin L.H. (Eds). TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours. 5th edn. (2005), Springer-Verlag, Heidelberg 250-254